CRNX Crinetics Pharmaceuticals Inc.

22.81
+0.13  (+1%)
Previous Close 22.68
Open 22.48
Price To Book 4.26
Market Cap 552,510,572
Shares 24,222,296
Volume 45,086
Short Ratio
Av. Daily Volume 69,553
Stock charts supplied by TradingView

NewsSee all news

  1. Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  2. Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  3. Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  4. Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  5. Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 dosing of first patients announced March 19, 2019.
CRN00808 - ACROBAT EVOLVE
Acromegaly
Phase 1 top-line data due early 2020.
CRN01941
Neuroendocrine tumors

Latest News

  1. Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  2. Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  3. Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  4. Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for

  5. Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for